Treatment for H. pylori infection: New challenges with antimicrobial resistance

Journal of Clinical Gastroenterology

Volumn 47, Issue 5, 2013, Pages 383-388

  Vakil, Nimish ^a   Vaira, Dino ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

H. pylori treatment; quadruple therapy; sequential therapy; triple therapy

Indexed keywords

AMOXICILLIN; BISMUTH; BISMUTH CITRATE; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; DRUG SUBSTITUTION; HELICOBACTER INFECTION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; STOMACH PH; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RIFABUTIN; TREATMENT OUTCOME;

EID: 84876412884     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318277577b     Document Type: Review

References (41)

1. Sherwood P, Wibawa J, Atherton J, et al. Impact of acid secretion, gastritis and mucus thickness on gastric transfer of antibiotics in rats. Gut. 2002;51:490-494
2. Goddard A. Review article: Factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther. 1998;12:1175-1184
3. Erah P, Goddard A, Barrett D, et al. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39:5-12
4. Cockburn J, Gibberd RW, Reid AL, et al. Determinants of non-compliance with short-Term antibiotic regimens. Br Med J (Clin Res Ed). 1987;295:814-818
5. Vakil N, Cutler A. Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Am J Gastroenterol. 1999;94:1197-1199
6. Goodwin A, Kersulyte D, Sisson G, et al. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol. 1998;28:383-393
7. Houben M, van de Beek D, Hensen E, et al. A systematic review of helicobacter eradication therapy-The impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047-1055
8. Mégraud F. H. pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut. 2004;53:1374-1384
9. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2012. [Epub ahead of print
10. Chung JW, Lee GH, Jeong JY, et al. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol. 2012;27:493-497
11. Nishizawa T, Suzuki H, Matsuzaki J, et al. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob Agents Chemother. 2011;55:5374-5375
12. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004;10:1088-1094
13. Sharma VK, Howden CW. A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection. J Clin Gastroenterol. 2004;38:326-331
14. Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: Multicentre randomised controlled trial (MRC-CUBE trial). BMJ. 2008;336:651-654
15. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: Results of three US multicenter, doubleblind trials. Am J Gastroenterol. 2000;95:3393-3398
16. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562-567
17. Laine L, Suchower L, Frantz J, et al. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: Results of three multicenter, double-blind, United States trials. Am J Gastroenterol. 1998;93:2106-2112
18. Fennerty MB, Kovacs TO, Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med. 1998;158:1651-1656
19. Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-Therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: Results of two double-blind, randomized studies. Helicobacter. 2003;8:626-642
20. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99-107
21. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial. Lancet. 2011;378:507-514
22. Qasim A, Sebastian S, Thornton O, et al. Rifabutin-And furazolidone-based Helicobacter pylori eradication therapies after failure of standard first-And second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther. 2005;21:91-96
23. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by the Maastricht III consensus conference and a third line empirical regimen. Am J Gastroenterol. 2009;104:21-25
24. Gisbert JP, Gisbert JL, Marcos S, et al. Empirical rescue therapy after Helicobacter pylori treatment failure: A singlecentre study of 500 patients. Aliment Pharmacol Ther. 2008; 27:346-354
25. Katelaris PH, Forbes GM, Talley NJ, et al. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology. 2002;123:1763-1769
26. Calvet X, Ducons J, Guardiola J, et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection-A randomized trial. Aliment Pharmacol Ther. 2002;16:1261-1267
27. Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-Analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73
28. O'Morain C, Borody T, Farley A, et al. Efficacy and safety of single-Triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: An international multicentre study. Aliment Pharmacol Ther. 2003;17:415-420
29. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, openlabel, non-inferiority, phase 3 trial. Lancet. 2011;377:905-913
30. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34
31. Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106:1970-1975
32. Rinaldi V, Zullo A, Pugliano F, et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 1997;11:929-933
33. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial. Ann Intern Med. 2007;146:556-563
34. Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: Systematic review and meta-Analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104:3069-3079
35. Park HG, Jung MK, Jung JT, et al. Randomised clinical trial: A comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment Pharmacol Ther. 2012;35:56-65
36. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol. 2010;8:36-41
37. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: A meta-Analysis. Am J Gastroenterol. 2006;101:488-496
38. Jeong MH, Chung JW, Lee SJ, et al. Comparison of rifabutinand levofloxacin-based third-line rescue therapies for Helicobacter pylori Korean. J Gastroenterol. 2012;59:401-406
39. Gisbert JP, Gisbert JL, Marcos S, et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24:1469-1474
40. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourthline rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35:941-947
41. Vakil N, Vaira D. Sequential therapy for Helicobacter pylori: Time to consider making the switch? JAMA. 2008;300: 1346-1347